Cited by 350Multiple Myeloma Research and TreatmentsBone health and treatmentsChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Updated Diagnostic Criteria and Staging System for Multiple Myeloma

Rajkumar, S. Vincent·2016·American Society of Clinical Oncology Educational Book

Open this paper in CoChat — free account

Abstract

There has been remarkable progress made in the diagnosis and treatment of multiple myeloma (MM). The median survival of the disease has doubled as a result of several new active drugs. These advances have necessitated a revision of the disease definition and staging of MM. Until recently, MM was defined by the presence of end-organ damage, specifically hypercalcemia, renal failure, anemia, and bone lesions (CRAB features) that can be attributed to the clonal process. In 2014, the International Myeloma Working Group (IMWG) updated the diagnostic criteria for MM to add three specific biomarkers that can be used to diagnose the disease in patients who did not have CRAB features: clonal bone marrow plasma cells greater than or equal to 60%, serum free light chain (FLC) ratio greater than or equal to 100 provided involved FLC level is 100 mg/L or higher, or more than one focal lesion on MRI. In addition, the definition was revised to allow CT and PET-CT to diagnose MM bone disease. These changes enable early diagnosis and allow the initiation of effective therapy to prevent the development of end-organ damage for patients who are at the highest risk. A new staging system has been developed that incorporates high-risk cytogenetic abnormalities in addition to standard laboratory markers of prognosis.

Integrity signals

Registry

Crossref · 10.1200/edbk_159009

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citation
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citation
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citation
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Self-citation
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Self-citation
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Self-citation
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568

Flagged first, then by citations

Show all 33 references

Sorted by citations

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., Miguel, J. F. S., Sonneveld, P., Mateos, M., Zamagni, E., Avet‐Loiseau, H., Hájek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 901
Bone metastases
Coleman, R. E., Croucher, P. I., Padhani, A. R., Clézardin, P., Chow, E., Fallon, M., Guise, T. A., Colangeli, S., Capanna, R., & Costa, L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00216-3 · Cited by 625
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Mikhael, J. R., Ismaila, N., Cheung, M. C., Costello, C. L., Dhodapkar, M. V., Kumar, S. K., Lacy, M. Q., Lipe, B. C., Little, R. F., Nikonova, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02096 · Cited by 344
Epidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Dimopoulos, M. A., Hungria, V., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, Â., Pappa, V., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00243-0 · Cited by 146
A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies
Thapa, R., Gupta, G., Bhat, A. A., Almalki, W. H., Alzarea, S. I., Kazmi, I. A., Saleem, S., Khan, R., Altwaijry, N., Dureja, H., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127375 · Cited by 139
Emerging role of exosomes as biomarkers in cancer treatment and diagnosis
Hanjani, N. A., Esmaelizad, N., Zanganeh, S., Gharavi, A. T., Heidarizadeh, P., Radfar, M., Omidi, F., MacLoughlin, R. J., & Doroudian, M. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103565 · Cited by 131
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Eleutherakis‐Papaiakovou, E., Kanellias, N., Kastritis, E., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2020) · Journal of Oncology · doi:10.1155/2020/7131802 · Cited by 92
Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC)
Mikhail, F. M., Biegel, J. A., Cooley, L. D., Dubuc, A. M., Hirsch, B. A., Horner, V. L., Newman, S., Shao, L., Wolff, D. J., & Raca, G. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0545-7 · Cited by 83
Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)
Ho, M., Patel, A. S., Goh, C. Y., Moscvin, M., Zhang, L., & Bianchi, G. (2020) · Leukemia · doi:10.1038/s41375-020-01051-x · Cited by 83
Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma
Zaleta, A. K., Miller, M. F., Olson, J. S., Yuen, E. Y. N., LeBlanc, T. W., Cole, C. E., McManus, S., & Buzaglo, J. S. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7561 · Cited by 59
The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma
Wang, L., Lin, N., & Li, Y. (2019) · Oncology Reports · doi:10.3892/or.2019.6968 · Cited by 58
Circulating exosomal long noncoding RNA PRINS—First findings in monoclonal gammopathies
Sedlaříková, L., Bollová, B., Radová, L., Brožová, L., Jarkovský, J., Almáši, M., Penka, M., Kuglík, P., Sandecká, V., Štork, M., et al. (2018) · Hematological Oncology · doi:10.1002/hon.2554 · Cited by 52
Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
Fakhri, B., Fiala, M. A., Tuchman, S. A., & Wildes, T. M. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.01.005 · Cited by 50
Screening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice
Genzen, J. R., Murray, D. L., Ábel, G., Meng, Q. H., Baltaro, R. J., Rhoads, D. D., Delgado, J. C., Souers, R. J., Bashleben, C. P., Keren, D. F., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0128-cp · Cited by 46
Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment
Das, S., Juliana, N., Yazit, N. A. A., Azmani, S., & Abu, I. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031649 · Cited by 46
Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma
Luo, Y., & Gui, R. (2020) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2020.2020.0243 · Cited by 45
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
Schinke, C., Boyle, E. M., Ashby, C., Wang, Y., Lyzogubov, V. V., Wardell, C. P., Qu, P., Hoering, A., Deshpande, S., Ryan, K. R., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0336-z · Cited by 43
Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment
Urbán, V. S., Ceglédi, A., & Mikala, G. (2022) · GeroScience · doi:10.1007/s11357-022-00698-x · Cited by 43
An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring
Rafae, A., Malik, M. N., Zar, M. A., Durer, S., & Durer, C. (2018) · Cureus · doi:10.7759/cureus.3148 · Cited by 40
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 43
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
Hernández‐Rivas, J., Ríos, R., Encinas, C., Alonso, R., & Lahuerta, J. J. (2022) · Biomarker Research · doi:10.1186/s40364-021-00344-2 · Cited by 40
Extramedullary Multiple Myeloma: Challenges and Opportunities
Ho, M., Paruzzo, L., Minehart, J. C., Nabar, N. R., Noll, J. H., Luo, T., Garfall, A. L., & Zanwar, S. (2025) · Current Oncology · doi:10.3390/curroncol32030182 · Cited by 39
Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis
Wang, Y., Lin, Q., Song, C., Ma, R., & Li, X. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1839701 · Cited by 38
Imaging of Malignant Primitive Tumors of the Spine
Mechri, M., Riahi, H., Sboui, I., Bouaziz, M. C., Vanhoenacker, F. M. H. M., & Ladeb, M. F. (2018) · Journal of the Belgian Society of Radiology · doi:10.5334/jbsr.1410 · Cited by 36
Targeting multiple myeloma with natural polyphenols
Pojero, F., Poma, P., Spanò, V., Montalbano, A., Barraja, P., & Notarbartolo, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.041 · Cited by 35
The Role of18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems
Deng, S., Zhang, B., Zhou, Y., Xu, X., Li, J., Sang, S., & Zhang, W. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/4198673 · Cited by 32
ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma
Zmorzyński, S., Szudy‐Szczyrek, A., Popek-Marciniec, S., Korszeń-Pilecka, I., Wojcierowska-Litwin, M., Luterek, M., Chocholska, S., Styk, W., Świderska-Kołacz, G., Januszewska, J., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00044 · Cited by 33
Amyloid in bone marrow smears in systemic light-chain amyloidosis
Kimmich, C. R., Schönland, S. O., Kräker, S., Andrulis, M., Ho, A. D., Mayer, G., Dittrich, T., Hundemer, M., & Hegenbart, U. (2017) · Amyloid · doi:10.1080/13506129.2017.1314959 · Cited by 30
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Cornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J. J., Jagasia, M., Patton, D., Harrell, S. L., Hall, R., Wyatt, H., & Piazza, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00045 · Cited by 30
Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
Elboğa, U., Şahin, E., Çayırlı, Y. B., Okuyan, M., Aktaş, G., Şahin, H. H., Doğan, İ., Kuş, T., Akkurd, D. M., Çimen, U., et al. (2022) · Tomography · doi:10.3390/tomography8010024 · Cited by 29
An Automated Pipeline for Differential Cell Counts on Whole-Slide Bone Marrow Aspirate Smears
Lewis, J. E., Shebelut, C. W., Drumheller, B. R., Zhang, X., Shanmugam, N., Attieh, M., Horwath, M. C., Khanna, A., Smith, G. H., Gutman, D. A., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100003 · Cited by 29
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance
Nielsen, T., Kristensen, S. R., Gregersen, H., Teodorescu, E. M., & Pedersen, S. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.03.015 · Cited by 29
A Qualitative Study of the Experiences of Living With Multiple Myeloma
LeBlanc, M. R., LeBlanc, T. W., Bryant, A. L., Pollak, K. I., Bailey, D. E., & Smith, S. K. (2021) · Oncology nursing forum · doi:10.1188/21.onf.151-160 · Cited by 26
Nontargeted and targeted metabolomics approaches reveal the key amino acid alterations involved in multiple myeloma
Yue, L., Zeng, P., Li, Y., Chai, Y., Wu, C., & Gao, B. (2022) · PeerJ · doi:10.7717/peerj.12918 · Cited by 26
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
Oudaert, I., der Vreken, A. V., Maes, A., Bruyne, E. D., Veirman, K. D., Vanderkerken, K., & Menu, E. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00303-z · Cited by 27
Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances
Garderet, L., D’Souza, A., Jacobs, P., van Biezen, A., Schönland, S. O., Kröger, N. M., Morris, C., & Hari, P. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.009 · Cited by 27
Prognostic value of the albumin–globulin ratio and albumin–globulin score in patients with multiple myeloma
Cai, Y., Zhao, Y., Dai, Q., Xu, M., Xu, X., & Xia, W. (2021) · Journal of International Medical Research · doi:10.1177/0300060521997736 · Cited by 26
Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment
Sharma, R., Jain, A., Jandial, A., Lad, D. P., Khadwal, A., Prakash, G., Nada, R., Aggarwal, R., Ramachandran, R., Varma, N., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.04.013 · Cited by 25
Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy
Ümıt, E. G., Baysal, M., Baş, V., Asker, I., Kırkızlar, H. O., & Demir, A. M. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219835303 · Cited by 25
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
Vià, M. D., Ziccheddu, B., Maeda, A., Bagnoli, F., Perrone, G., & Bolli, N. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000502 · Cited by 27
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 25
Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma
Papadimitriou, K., Kostopoulos, I. V., Tsopanidou, A., Orologas‐Stavrou, N., Kastritis, E., Tsitsilonis, O., Dimopoulos, M. A., & Terpos, E. (2020) · Cancers · doi:10.3390/cancers12082006 · Cited by 23
Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment
Lopes, R., Caetano, J., Barahona, F., Pestana, C., Ferreira, B. V., Lourenço, D., Queirós, A. C., Bilreiro, C., Shemesh, N., Beck, H. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909880 · Cited by 23
Blockade of SDF‐1/CXCR4 reduces adhesion‐mediated chemoresistance of multiple myeloma cells via interacting with interleukin‐6
Liu, Y., Liang, H., Lv, Y., Tang, S., & Peng, C. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28570 · Cited by 22
Dual-Energy CT-Based Bone Marrow Imaging in Multiple Myeloma: Assessment of Focal Lesions in Relation to Disease Status and MRI Findings
Werner, S., Krauß, B., & Horger, M. (2021) · Academic Radiology · doi:10.1016/j.acra.2021.01.029 · Cited by 22
IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases
Angelova, E. A., Li, S., Wang, W., Bueso-Ramos, C., Tang, G., Medeiros, L. J., & Lin, P. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.09.008 · Cited by 21
Survival Outcomes of Newly Diagnosed Multiple Myeloma at a Tertiary Care Center in North India (IMAGe: 001A Study)
Yanamandra, U., Sharma, R., Shankar, S., Yadav, S., Kapoor, R., Pramanik, S. K., Ahuja, A., Kumar, R., Sharma, S., Das, S., et al. (2021) · JCO Global Oncology · doi:10.1200/go.20.00625 · Cited by 21
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Nadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55308-5 · Cited by 20
Human myeloma cell‐ and plasma‐derived extracellular vesicles contribute to functional regulation of stromal cells
Reale, A., Carmichael, I., Xu, R., Mithraprabhu, S., Khong, T. T., Chen, M., Fang, H., Savvidou, I., Ramachandran, M., Bingham, N. E., et al. (2021) · PROTEOMICS · doi:10.1002/pmic.202000119 · Cited by 20
Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma
Zorlu, T., Kayer, M. A., Okumus, N., Ulaş, T., Dal, M. S., & Altuntaş, F. (2025) · Diagnostics · doi:10.3390/diagnostics15131708 · Cited by 19
Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study
Xu, J., Wang, M., Shen, Y., Yan, M., Xie, W., Wang, B., Liu, H., & Cen, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287922 · Cited by 19
PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
Lee, B.-H., Kim, J.-H., Kang, K.-W., Lee, S.-R., Park, Y., Sung, H.-J., & Kim, B.-S. (2022) · Biomedicines · doi:10.3390/biomedicines10051099 · Cited by 19
An Evidence-Based Approach to Myeloma Bone Disease
Bingham, N. E., Reale, A., & Spencer, A. G. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0370-5 · Cited by 19
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
Bujarski, S. E., Udd, K. A., Soof, C. M., Chen, H., Spektor, T. M., Safaie, T., Li, M., Stern, J., Wang, C., Xu, N., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00821-6 · Cited by 19
CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET
Sharma, A., Gupta, K., Mishra, A., Lofland, G., Marsh, I. R., Kumar, D., Ghiaur, G., Imus, P. H., Rowe, S. P., Hobbs, R. F., et al. (2024) · Advanced Science · doi:10.1002/advs.202308617 · Cited by 18
Hematologic Diseases
Sankar, V., & Villa, A. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch17 · Cited by 18
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Byun, J. M., Min, C., Kım, K., Bang, S., Lee, J., Kim, J. S., Yoon, S., & Koh, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01374-5 · Cited by 17
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
Fonseca, R., Tran, D., Laidlaw, A., Rosta, E., Rai, M., Duran, J., & Ammann, E. M. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.005 · Cited by 17
Biochemical phenotyping of multiple myeloma patients at diagnosis reveals a disorder of mitochondrial complexes I and II and a Hartnup-like disturbance as underlying conditions, also influencing different stages of the disease
da Silva, I. D. C. G., Levatti, E. V. D. C., Pedroso, A. P., Marchioni, D. M. L., Carioca, A. A. F., & Colleoni, G. W. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-75862-4 · Cited by 17
Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging
Treitl, M., Ricke, J., & Baur‐Melnyk, A. (2021) · Skeletal Radiology · doi:10.1007/s00256-021-03799-4 · Cited by 17
Identification of patients at high risk of secondary extramedullary multiple myeloma development
Štork, M., Ševčı́ková, S., Minařík, J., Krhovská, P., Radocha, J., Pospíšilová, L., Brožová, L., Jarkovský, J., Špıčka, I., Štraub, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17925 · Cited by 17
Inflammation and Oxidative Stress in Seminal Plasma: Search for Biomarkers in Diagnostic Approach to Male Infertility
Bruno, C., Basile, U., Vergani, E., Napodano, C., Oliva, A., Gulli, F., Meucci, E., Silvestrini, A., Orlando, P., Silvestri, S., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060857 · Cited by 17
11C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET/CT and Prognostic Value
Morales-Lozano, M. I., Rodríguez‐Otero, P., Sancho, L., Núñez-Córdoba, J. M., Prieto, E., Marcos‐Jubilar, M., Rosales, J. J., Piérola, A. A., Guillén, E. F., Miguel, J. F. S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179895 · Cited by 17
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
Szabo, A. G., Iversen, K. F., Möller, S., & Plesner, T. (2019) · Clinical Hematology International · doi:10.2991/chi.d.190805.002 · Cited by 17
Clinically‐suspected cast nephropathy: A retrospective, national, real‐world study
Szabo, A. G., Thorsen, J., Iversen, K. F., Hansen, C. T., Teodorescu, E. M., Pedersen, S. B., Flæng, S. B., Strandholdt, C. N., Frederiksen, M., Vase, M. Ø., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25959 · Cited by 16
Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature
Naymagon, L., & Abdul‐Hay, M. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2087-7 · Cited by 16
Real-World Treatment Patterns, Healthcare Resource Use and Disease Burden in Patients with Multiple Myeloma in Europe
Martínez‐López, J., Bailey, A., Lambert, A., Luke, E., Ribbands, A., Erler-Yates, N., Valluri, S., Haefliger, B., & Gay, F. (2023) · Future Oncology · doi:10.2217/fon-2023-0021 · Cited by 16
Proteomics-inspired precision medicine for treating and understanding multiple myeloma
Ho, M., Bianchi, G., & Anderson, K. C. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1732205 · Cited by 16
Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma
Reale, A., Khong, T. T., Xu, R., Chen, M., Mithraprabhu, S., Bingham, N. E., Spencer, A. G., & Greening, D. W. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1186-9_10 · Cited by 15
Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre
Morè, S., Corvatta, L., Manieri, V. M., Olivieri, A., & Offidani, M. (2023) · British Journal of Haematology · doi:10.1111/bjh.18658 · Cited by 15
Whole body imaging in musculoskeletal oncology: when, why, and how
Vicentini, J. R. T., & Bredella, M. A. (2022) · Skeletal Radiology · doi:10.1007/s00256-022-04112-7 · Cited by 14
Monoclonal Gammopathy of Undetermined Significance
(2018) · Elsevier eBooks · doi:10.1016/b978-0-323-39254-9.50156-2 · Cited by 14
Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
Gerov, V., Gerova, D., Micheva, I., Nikolova, M., Mihaylova, G., & Galunska, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134440 · Cited by 13
Natural Language Processing–Assisted Classification Models to Confirm Monoclonal Gammopathy of Undetermined Significance and Progression in Veterans' Electronic Health Records
Wang, M., Yu, Y., Liu, L., Schoen, M. W., Kumar, A., Vargo, K., Colditz, G. A., Thomas, T. S., & Chang, S. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00081 · Cited by 13
Mechanisms of resistance to venetoclax in hematologic malignancies
Zielonka, K., & Jamroziak, K. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/181145 · Cited by 14
Enhancing diagnostic accuracy of multiple myeloma through ML-driven analysis of hematological slides: new dataset and identification model to support hematologists
Andrade, C. L. B., Ferreira, M. V. F., Alencar, B. M., Junior, A. M. A., Lopes, T. J. S., dos Santos, A. S., dos Santos, M. M., Silva, M. I. C. S. E., Rosa, I. M. D. R. P., Filho, J. L. S. B., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61420-9 · Cited by 13
In vitro facilitating role of polygonatum sibiricum polysaccharide in osteogenic differentiation of bone marrow mesenchymal stem cells from patients with multiple myeloma
Zhao, J., Ma, L., Ni, Z., & Liu, H. (2021) · Biotechnology Letters · doi:10.1007/s10529-021-03125-x · Cited by 13
Ocular complications of plasma cell dyscrasias
Singh, R. B., Singhal, S., Sinha, S., Cho, J., Nguyen, A. X.-L., Dhingra, L. S., Kaur, S., Sharma, V., & Agarwal, A. K. (2023) · European Journal of Ophthalmology · doi:10.1177/11206721231155974 · Cited by 13
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Mettias, S., ElSayed, A., Moore, J., & Berenson, J. R. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01122-4 · Cited by 12
Fat fraction quantification of lumbar spine: comparison of T1-weighted two-point Dixon and single-voxel magnetic resonance spectroscopy in diagnosis of multiple myeloma
Pei, X.-J., Lian, Y.-F., Yan, Y., Jiang, T., Liu, A., Shi, Q., & Pan, Z. (2020) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2020.19401 · Cited by 12
Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute
Okello, C. D., Mulumba, Y., Omoding, A., Ddungu, H., Welch, K., Thompson, C. L., Cowan, A. J., Cooney, M. M., & Orem, J. (2021) · African Health Sciences · doi:10.4314/ahs.v21i1.11 · Cited by 12
A polygenic risk score for multiple myeloma risk prediction
Canzian, F., Piredda, C., Macauda, A., Zawirska, D., Andersen, N. F., Nagler, A., Zaucha, J. M., Mazur, G. J., Dumontet, C., Wątek, M., et al. (2021) · European Journal of Human Genetics · doi:10.1038/s41431-021-00986-8 · Cited by 12
Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
Dunphy, K., Bazou, D., Henry, M. A., Meleady, P., Miettinen, J. J., Heckman, C. A., Dowling, P., & O’Gorman, P. (2023) · Cancers · doi:10.3390/cancers15153764 · Cited by 12
Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
Lee, B., Park, Y., Kim, J.-H., Kang, K., Lee, S. J., Kim, S. J., & Kim, B. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.669817 · Cited by 12
Symptom burden and health-related quality of life impacts of smoldering multiple myeloma: the patient perspective
Jean‐Baptiste, M., Gries, K. S., Lenderking, W. R., & Fastenau, J. M. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00253-2 · Cited by 11
Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
Pasiarski, M., Sosnowska‐Pasiarska, B., Grywalska, E., Stelmach-Gołdyś, A., Kowalik, A., Góźdź, S. S., & Roliński, J. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s220423 · Cited by 11
Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo
Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., Mrozik, K. M., Vandyke, K., Mukherjee, S., Davies, G., et al. (2020) · Cancers · doi:10.3390/cancers12082149 · Cited by 11
Risk Factors for Catheter-Related Thrombosis in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Hoppe, A., Rupa‐Matysek, J., Małecki, B., Dytfeld, D., Hoppe, K., & Gil, L. (2021) · Medicina · doi:10.3390/medicina57101020 · Cited by 11
Multiple myeloma – 2020 update on diagnosis and management
Charliński, G., & Jurczyszyn, A. J. (2020) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2020.0035 · Cited by 10
Role of FDG PET in the staging of multiple myeloma
Vicentini, J. R. T., & Bredella, M. A. (2021) · Skeletal Radiology · doi:10.1007/s00256-021-03771-2 · Cited by 10
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Summary
Mikhael, J. R., Ismaila, N., & Martin, T. G. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00782 · Cited by 10
Expression of hsa-MIR-204, RUNX2, PPARγ, and BCL2 in Bone Marrow Derived Mesenchymal Stem Cells from Multiple Myeloma Patients and Normal Individuals.
Mansurabadi, R., Abroun, S., Hajifathali, A., Kojabad, A. A., Atashi, A., & Haghighi, M. (2017) · Europe PMC (PubMed Central) · doi:10.22074/cellj.2017.4480 · Cited by 10
Inter-observer agreement of baseline whole body MRI in multiple myeloma
Croft, J., Riddell, A. M., Koh, D., Downey, K., Blackledge, M., Usher, M., Boyd, K. D., Kaiser, M., & Messiou, C. (2020) · Cancer Imaging · doi:10.1186/s40644-020-00328-9 · Cited by 10
LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
Bútová, R., Vychytilová-Faltejsková, P., Gregorová, J., Radová, L., Almáši, M., Bezděková, R., Brožová, L., Jarkovský, J., Knechtová, Z., Štork, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9111637 · Cited by 10
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
Prawitz, T., Popat, R., Suvannasankha, A., Sarri, G., Hughes, R. L., Wang, F., Hogea, C. S., Ferrante, S. A., Gorsh, B., Willson, J., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01884-7 · Cited by 10
Multiple myeloma in elderly patients—a Portuguese multicentric real-life study
Joao, C. M., Bergantim, R., Neves, M. L., Chacim, S. P., Afonso, C., Barradas, J., Bernardo, M., Coelho, H. G. B., Esteves, G. V., Fraga, C., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03640-y · Cited by 10
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades
Pasvolsky, O., Marcoux, C., Dai, J., Milton, D. R., Tanner, M. R., Syed, N., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.001 · Cited by 10
Steatotic liver disease in the context of hematological malignancies and anti-neoplastic chemotherapy
Pontikoglou, C. G., Filippatos, T. D., Matheakakis, A., & Papadaki, H. Α. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156000 · Cited by 9
Multiple Myeloma: Possible Cure from the Sea
Capalbo, A., & Lauritano, C. (2022) · Cancers · doi:10.3390/cancers14122965 · Cited by 9

Authors: Rajkumar, S. V.
Affiliations: Mayo Clinic (US)
Corresponding author: Rajkumar, S. Vincent
ORCID: Rajkumar, S. Vincent
Venue: American Society of Clinical Oncology Educational Book
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2016-05
Volume: 36
Issue: 36
Pages: e418-e423
ISSN: 1548-8748 (ISSN-L)
1548-8756
DOI: 10.1200/edbk_159009
OpenAlex: W4245689579
Cited by: 350
References: 33
Citations by year: 2026: 29 · 2025: 37 · 2024: 46 · 2023: 50 · 2022: 52 · 2021: 50 · 2020: 32 · 2019: 23 · 2018: 17 · 2017: 14
FWCI: 2.56
Type: journal article
Language: en
Open access: closed
Locations: American Society of Clinical Oncology Educational Book (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords: multiple myeloma, diagnostic criteria, disease staging, serum free light chain ratio, bone lesions, high-risk cytogenetics, prognosis
MeSH terms: Positron Emission Tomography Computed Tomography, Bone Marrow Cells, Humans, Magnetic Resonance Imaging, Multiple Myeloma, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Updated Diagnostic Criteria and Staging System for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks